Condition: Hepatocellular Carcinoma · HCC · Sponsor: University of California, Irvine
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
This description comes directly from the study's public registry record.
Chao Family Comprehensive Cancer Center University of California, Irvine · 1-877-827-7883 · ucstudy@uci.edu
University of California Irvine Medical
Always discuss trial participation with your own doctor first.
| Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04472767